HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $452,000 | -81.0% | 10,272 | -82.8% | 0.03% | -78.2% |
| Q1 2022 | $2,384,000 | +67.9% | 59,782 | +69.3% | 0.16% | -11.9% |
| Q4 2021 | $1,420,000 | +55.9% | 35,318 | +57.6% | 0.18% | +46.3% |
| Q3 2021 | $911,000 | -42.5% | 22,405 | -74.9% | 0.12% | -74.4% |
| Q4 2019 | $1,584,000 | +63.3% | 89,363 | +42.8% | 0.47% | +30.7% |
| Q3 2019 | $970,000 | -15.1% | 62,562 | -6.0% | 0.36% | -14.2% |
| Q2 2019 | $1,143,000 | +54.5% | 66,537 | +44.8% | 0.42% | -0.2% |
| Q1 2019 | $740,000 | -48.7% | 45,965 | -53.4% | 0.42% | +5.2% |
| Q4 2018 | $1,443,000 | +21.5% | 98,601 | +50.8% | 0.40% | +57.0% |
| Q3 2018 | $1,188,000 | +64.5% | 65,394 | +52.9% | 0.26% | +70.7% |
| Q2 2018 | $722,000 | +54.6% | 42,769 | +79.5% | 0.15% | +66.7% |
| Q1 2018 | $467,000 | +253.8% | 23,830 | +56.0% | 0.09% | +66.7% |
| Q2 2016 | $132,000 | – | 15,272 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |